Show simple item record

dc.contributor.authorRushton, Sarah
dc.contributor.authorBurghel, G
dc.contributor.authorWallace, A
dc.contributor.authorNonaka, Daisuke
dc.date.accessioned2016-04-18T08:43:19Zen
dc.date.available2016-04-18T08:43:19Zen
dc.date.issued2016-03-14en
dc.identifier.citationImmunohistochemical Detection of BRAF V600E Mutation Status in Anaplastic Thyroid Carcinoma. 2016: Histopathologyen
dc.identifier.issn1365-2559en
dc.identifier.pmid26987976en
dc.identifier.doi10.1111/his.12964en
dc.identifier.urihttp://hdl.handle.net/10541/605663en
dc.description.abstractAnaplastic thyroid carcinoma (ATC) is one of the most aggressive adult solid cancers. Due to its rarity, there are only a handful of molecular genetics studies on ATCs (1-3) . BRAF V600E mutation is one of the commonly reported genetic alterations, reported in10-68% of ATCs(1-4) . Currently there is no effective treatment for ATC.,Therapy targeting BRAF may provide a potential therapeutic option as a dramatic response to BRAF inhibitor (vemurafenib) has been reported in a case of BRAF-mutated ATC (5) . A number of studies have shown that BRAF V600E mutant-specific antibody VE1 can identify BRAF V600E mutation in a spectrum of cancers, including thyroid cancers (6) . We investigated the utility of this antibody for BRAF V600E screening in ATCs. This article is protected by copyright. All rights reserved.
dc.languageENGen
dc.language.isoenen
dc.rightsArchived with thanks to Histopathologyen
dc.titleImmunohistochemical detection of BRAF V600E mutation status in anaplastic thyroid carcinoma.en
dc.typeArticleen
dc.contributor.departmentDepartment of Histopathology, Christie NHS Foundation Trust, Manchester, UKen
dc.identifier.journalHistopathologyen
html.description.abstractAnaplastic thyroid carcinoma (ATC) is one of the most aggressive adult solid cancers. Due to its rarity, there are only a handful of molecular genetics studies on ATCs (1-3) . BRAF V600E mutation is one of the commonly reported genetic alterations, reported in10-68% of ATCs(1-4) . Currently there is no effective treatment for ATC.,Therapy targeting BRAF may provide a potential therapeutic option as a dramatic response to BRAF inhibitor (vemurafenib) has been reported in a case of BRAF-mutated ATC (5) . A number of studies have shown that BRAF V600E mutant-specific antibody VE1 can identify BRAF V600E mutation in a spectrum of cancers, including thyroid cancers (6) . We investigated the utility of this antibody for BRAF V600E screening in ATCs. This article is protected by copyright. All rights reserved.


This item appears in the following Collection(s)

Show simple item record